-+ 0.00%
-+ 0.00%
-+ 0.00%

Inhibikase Therapeutics Names Scott M. Wasserman to Board

PUBT·11/10/2026 21:05:23
Listen to the news
Inhibikase Therapeutics Names Scott M. Wasserman to Board
  • Inhibikase Therapeutics announced Scott M. Wasserman's appointment to its board in October 2026.
  • Wasserman is Kailera Therapeutics' chief medical officer, a cardiologist with more than two decades of clinical development and company leadership experience.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibikase Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611101601PRIMZONEFULLFEED9874613) on November 10, 2026, and is solely responsible for the information contained therein.